ImmunoBrain, a New York–based clinical-stage company, presented Phase Ib data for IBC-Ab002, an anti-PD-L1 monoclonal antibody in early Alzheimer’s disease, at the AD/PD 2026 conference in Copenhagen — among the first clinical datasets applying immune checkpoint blockade in neurodegeneration.
The trial, IBC-01-01 (NCT05551741), is a randomized, double-blind, placebo-controlled Phase Ib study that enrolled 40 patients with early Alzheimer’s disease across sites in the UK, the Netherlands, and Israel. Primary and secondary endpoints were safety, tolerability, and pharmacokinetics, with exploratory CSF biomarker assessments at 12 months. The trial met its primary objective of safety and tolerability, with no serious drug-related adverse events reported. All immune-related adverse events were mild and manageable, and no cases of amyloid-related imaging abnormalities were observed.
At a 30 mg/kg dose, IBC-Ab002 showed directionally favorable changes in cerebrospinal fluid biomarkers, including neurogranin, total tau, and pTau181, though the study was not powered to assess cognitive outcomes.
IBC-Ab002 blocks the PD-1/PD-L1 pathway to transiently activate peripheral immunity, with the aim of reducing neuroinflammation and supporting brain repair. The approach is mechanistically distinct from anti-amyloid therapies such as lecanemab and donanemab, which have shown modest efficacy but carry ARIA risks.
The data remain preliminary. The small Phase Ib study, with exploratory biomarker endpoints and no disclosed statistical analysis, does not establish clinical benefit. ImmunoBrain said it is designing a next-stage trial incorporating cognitive endpoints.